instead. Some patients may need more frequent monitoring, especially if symptoms change, and these suggestions should not be used to inform reimbursement decisions. There is substantial clinical variation from patient to patient that may affect testing frequency. For people with IIM-ILD and SSc-ILD, we suggest PFTs for monitoring every 3 to 6 months for the first year, then less frequently once stable. More frequent monitoring is needed early in the course of disease and in patients with active